Scotland says yes to Xeloda, Mepact, Tasigna and Prezista
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium, Scotland's health technology appraisal body, has this week announced positive recommendations for several drugs this week, including Roche's Xeloda (capecitabine), Janssen-Cilag's Prezista (darunavir), Takeda's Mepact (mifamurtide) and Novartis' Tasigna (nilotinib). Some of the drugs have not yet been approved for use on England's NHS.